PCRX - NASDAQ

Pacira BioSciences, Inc.

PCRX·NASDAQ

$22.48

+1.0%

HealthcareDrug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$884.35M

EPS0.1600

P/E Ratio140.52

Earnings Date08/04/2026

1.26B

Assets

-19%

3Y-25.0%

5Y-1.0%

10Y+223.0%

571.81M

Total Liabilities

-26%

3Y-37.0%

5Y-13.0%

10Y+232.0%

693.11M

Total Equity

-11%

3Y-11.0%

5Y+12.0%

10Y+217.0%

Pacira BioSciences, Inc. Funding & Solvency Profile

PCRX · NASDAQ

Current Assets

Cash & Cash Equivalents158.54M

Net Receivables124.07M

Inventory152.86M

Other Current Assets32.62M

Total Current Assets548 M

Non-Current Assets

Property, Plant & Equipment182.47M

Goodwill & Intangible Assets388.31M

Long-Term Investments0.00

Other Non-Current Assets22.31M

Total Non-Current Assets205 M

Total Assets

1.26B

Financial Health Analysis

Current Ratio

4.54x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.82x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

427 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

43% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Pacira BioSciences, Inc. Balance Sheet

PCRX • NASDAQ

Pacira BioSciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	158.5M	276.8M	153.3M	104.1M	585.6M	100M	78.2M	132.5M	54.1M	35.9M	159M	158.2M	12.5M	42.6M	46.2M	26.1M	7.1M	12.4M
Short-Term Investments	79.9M	207.8M	125.3M	184.5M	70.8M	421.7M	213.7M	250.9M	257.2M	136.7M	0.0	0.0	59.6M	0.0	30M	0.0	0.0	0.0
Cash & Short-Term Investments	238.4M	484.6M	278.6M	288.7M	656.4M	521.7M	292M	383.5M	311.3M	172.6M	159M	158.2M	72.2M	42.6M	76.2M	26.1M	7.1M	12.4M
Net Receivables	124.1M	113.3M	105.6M	98.4M	96.3M	53M	47.5M	38M	31.7M	29.9M	25.9M	22.4M	14.6M	4.4M	2.1M	1.2M	1.5M	2.6M
Accounts Receivables	124.1M	113.3M	105.6M	98.4M	96.3M	53M	47.5M	38M	31.7M	29.9M	25.9M	22.4M	14.6M	4.4M	2.1M	1.2M	1.5M	2.6M
Inventory	152.9M	125.3M	104.4M	96.1M	98.6M	64.7M	58.3M	48.6M	41.4M	31.3M	61.6M	29.3M	15.6M	12.1M	1.2M	1.6M	1.7M	2M
Prepaids	0.0	0.0	0.0	0.0	14.8M	12.3M	10.8M	7.9M	6.7M	9.3M	6.1M	4.5M	2.8M	1.9M	1.8M	812K	1.1M	1.2M
Other Current Assets	32.6M	21.9M	21.5M	15.2M	0.0	0.0	0.0	7.9M	6.7M	9.3M	6.1M	1.5M	1.6M	1.5M	1.3M	1.3M	1.2M	1.2M
Total Current Assets	548M	745.1M	510M	498.3M	866M	651.6M	408.6M	478M	391.1M	243.1M	252.6M	214.3M	106.8M	60.9M	82.6M	31.1M	12.5M	19.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	182.5M	216.4M	234.9M	254.4M	264.8M	211.2M	142.8M	108.7M	107M	101M	90.3M	60.6M	48.2M	39.1M	25.1M	24M	19.6M	18M
Goodwill	20.2M	0.0	163.2M	163.2M	145.2M	99.5M	99.5M	62M	55.2M	46.7M	30.9M	23.8M	10.3M	8.3M	0.0	0.0	0.0	0.0
Intangible Assets	368.1M	426M	483.3M	540.5M	624M	96.5M	104.4M	0.0	0.0	0.0	81K	403K	1.2M	3.2M	5.3M	8.9M	11.2M	13.1M
Goodwill & Intangible Assets	388.3M	426M	646.5M	703.8M	769.1M	196.1M	203.9M	62M	55.2M	46.7M	31M	24.2M	11.5M	12M	5.3M	8.9M	11.2M	13.1M
Long-Term Investments	0.0	29.4M	2.4M	37.2M	0.0	95.5M	64.8M	40M	74.2M	0.0	13.5M	24.4M	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	123.9M	130.4M	144.5M	160.3M	153.4M	106.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	22.3M	6.2M	36M	27.2M	22M	14M	11M	657K	825K	624K	2.3M	2.6M	3.4M	0.0	479K	2.6M	667K	63K
Total Non-Current Assets	716.9M	808.4M	1.1B	1.2B	1.2B	622.9M	422.5M	211.4M	237.3M	148.4M	137M	111.8M	63.1M	51.1M	30.8M	35.5M	31.4M	31.2M
Total Assets	1.3B	1.6B	1.6B	1.7B	2.1B	1.3B	831.1M	689.4M	628.4M	391.5M	389.6M	326.1M	169.8M	112.1M	113.5M	66.6M	44M	50.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	15.2M	19.1M	15.7M	15.2M	11M	10.5M	14.1M	14.4M	14.7M	7.6M	8.9M	6.9M	3.1M	2.6M	3.4M	6M	7M	11.8M
Accounts Payable	15.2M	19.1M	15.7M	15.2M	10.5M	10.4M	12.8M	14.4M	14.7M	7.5M	8.7M	6.8M	3.1M	2.6M	3.4M	6M	7M	11.8M
Other Payables	0.0	0.0	0.0	0.0	429K	114K	1.3M	0.0	76K	66K	208K	139K	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	51.3M	21.7M	63.6M	82.1M	48.8M	48.2M	44.3M	12.3M	11.2M	11.9M	8.9M	5.5M	1.6M	4.3M	3.3M	3.5M	1.7M
Short Term Debt	9.8M	201.8M	8.6M	33.6M	374.7M	149.6M	0.0	338K	324K	0.0	104M	103.4M	100M	0.0	7M	3.2M	0.0	0.0
Capital Lease Obligations (Current)	0.0	8.9M	8.8M	9.1M	7.9M	7.4M	4.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	429K	114K	1.3M	90K	76K	66K	208K	139K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	102K	595K	1.4M	1.4M	1M	972K	13.1M	2.3M	2.3M	2M
Other Current Liabilities	95.6M	28.8M	42.6M	26.2M	45.5M	36.9M	40.4M	1.6M	28.8M	25.4M	23.4M	19.4M	12.4M	9M	2.8M	1.6M	1.6M	1.4M
Total Current Liabilities	120.6M	309.9M	97.4M	147.8M	521.1M	253.3M	107.7M	60.7M	56.2M	44.8M	151.7M	140M	121.9M	14.2M	31.9M	16.3M	14.4M	17M
NON-CURRENT LIABILITIES
Long Term Debt	408.4M	383.5M	513.8M	655.8M	674.5M	313M	306M	290.6M	276.2M	108.7M	0.0	0.0	0.0	26M	18.5M	21.9M	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	10.1M	0.0	0.0	0.0	0.0	7.5M	8.1M	9.5M	3.2M	3.7M	8.4M	19.5M	21.6M	17.8M
Deferred Tax Liabilities (Non-Current)	4.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-105.9M	-103.1M	-99M	-3.7M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	2.5M	37.1M	38.3M	37.8M	67.4M	17.4M	21.5M	16.9M	16.5M	11.4M	11.5M	5.4M	3.4M	2.3M	4.8M	57.3M	30.9M	8.3M
Total Non-Current Liabilities	451.2M	465.2M	606.9M	758.4M	823.8M	401.5M	368.4M	307.5M	292.7M	127.7M	19.6M	14.9M	6.6M	32M	33.3M	98.6M	52.5M	26M
Capital Lease Obligations	36.2M	53.5M	63.6M	73.9M	79.6M	78.5M	45.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M	0.0	0.0	0.0
Total Liabilities	571.8M	775.2M	704.3M	906.2M	1.3B	654.8M	476.1M	368.1M	348.9M	172.5M	171.2M	154.9M	128.6M	46.2M	65.2M	114.9M	66.9M	43.1M
SHAREHOLDERS' EQUITY
Treasury Stock	-176.6M	-25.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2K	-2K	-2K	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6K	6K	6K
Common Stock	48K	47K	46K	46K	45K	44K	42K	41K	41K	37K	37K	36K	34K	33K	25K	1K	1K	1K
Additional Paid-In Capital	1.1B	1B	976.6M	924.1M	942.1M	873.2M	754M	709.7M	669M	565.2M	526.7M	481.3M	337.6M	298.3M	228.5M	88.5M	86.8M	85.5M
Retained Earnings	-199.3M	-206.4M	-106.8M	-148.8M	-211.9M	-253.9M	-399.4M	-388.2M	-389.1M	-346.2M	-308.3M	-310.1M	-296.4M	-232.5M	-180.2M	-136.9M	-109.8M	-78.1M
Accumulated Other Comprehensive Income/Loss	4.3M	343K	247K	-380K	167K	318K	322K	-280K	-454K	-30K	-52K	-80K	5K	27K	15K	-6.1M	-4.6M	-3.2M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1M	4.6M	0.0
Total Stockholders' Equity	693.1M	778.3M	870.1M	775M	730.4M	619.7M	354.9M	321.2M	279.5M	219M	218.4M	171.1M	41.2M	65.9M	48.3M	-48.4M	-22.9M	7.5M
Total Equity	693.1M	778.3M	870.1M	775M	730.4M	619.7M	354.9M	321.2M	279.5M	219M	218.4M	171.1M	41.2M	65.9M	48.3M	-48.4M	-22.9M	7.5M
SUMMARY
Total Liabilities & Equity	1.3B	1.6B	1.6B	1.7B	2.1B	1.3B	831.1M	689.4M	628.4M	391.5M	389.6M	326.1M	169.8M	112.1M	113.5M	66.6M	44M	50.5M
Total Investments	79.9M	237.3M	127.7M	221.7M	70.8M	517.2M	278.5M	290.9M	331.4M	136.7M	13.5M	24.4M	59.6M	0.0	30M	0.0	0.0	0.0
Total Debt	454.4M	638.9M	586M	763.4M	1.1B	541.1M	351.9M	290.9M	276.5M	108.7M	105.9M	103.1M	99M	26M	28.3M	25.1M	0.0	0.0
Net Debt	295.8M	362.1M	432.7M	659.3M	543.3M	441.2M	273.7M	158.4M	222.4M	72.8M	-53M	-55.1M	86.4M	-16.5M	-17.8M	-1.1M	-7.1M	-12.4M
Shares Outstanding	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433	45,487,433

SEC Filings

PCRX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 28, 2026	January 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 05, 2025	August 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 05, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 289 filings

Related Guides

Blog Categories

Continue your PCRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.